Diadexus

Diadexus is a diagnostics company based in South San Francisco, California. The company employs 23 people and generates $50 million in annual revenue. Diadexus develops and commercializes diagnostic products focused on predicting cardiac disease risk. Their products provide healthcare providers with actionable information to manage patients. The company is renowned for pioneering the testing of Lp-PLA2, a biomarker of vascular-specific inflammation. Their PLAC® Test ELISA Kit and PLAC® Test for Lp-PLA2 Activity are the only two FDA-cleared tests to measure Lp-PLA2. In addition to Lp-PLA2 tests, Diadexus is developing a pipeline of advanced cardiac biomarkers, including those for heart failure, proADM, proET-1, and proANP. Each of these biomarkers provides unique, complementary information for healthcare providers, going beyond currently available markers. Diadexus can be reached through their website at diadexus.com. They also offer services to pharmaceutical partners, helping them incorporate biomarkers into clinical development.